

Claims

1. Use of an inhibitor of S-adenosyl methionine decarboxylase (SAMDC) for the manufacture of a medicament intended for the prevention or the treatment of a herpes simplex virus infection.
5
2. The use according to claim 1, wherein said herpes simplex virus is HSV-1 or HSV-2.
3. The use according claim 1 or 2, wherein the inhibitor is administered in association with another agent efficient against a herpes simplex virus infection.
- 10 4. The use according to claim 3, wherein said agent is acyclovir.
5. The use according to any of claims 1 to 3, wherein said herpes simplex virus is a HSV-1 strain resistant to acyclovir and/or foscarnet and/or their derivatives.
6. The use according to any of preceding claims, wherein said medicament is intended for an administration to a non-human mammal.
- 15 7. The use according to any of claims 1 to 5, wherein said medicament is intended for an administration to a human.
8. The use according to claim 7, wherein said medicament is intended for an administration to an immunodepressed subject.
9. The use according to any one of preceding claims, wherein said inhibitor is
20 an inhibitor of SAMDC activity.
10. The use according to any one of the preceding claims, wherein said inhibitor inhibits the replication of HSV *in cellulo*.
11. The use according to claim 9 or 10, wherein said inhibitor is SAM486A.
12. The use according to any of claims 1 to 10, wherein said inhibitor is an
25 inhibitor of SAMDC expression.
13. The use according to claim 12, wherein said inhibitor is an antisense nucleic acid sequence that blocks expression of SAMDC.
14. A pharmaceutical composition comprising an inhibitor of S-adenosyl methionine decarboxylase and another agent efficient against a herpes simplex virus
30 infection, in a pharmaceutically acceptable carrier.

15. The pharmaceutical composition according to claim 14, wherein said agent is acyclovir.

16. The pharmaceutical composition according to claim 14 or 15, wherein said inhibitor is SAM486A.